Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Trial ID or NCT#

NCT01121588

Status

not recruiting iconNOT RECRUITING

Purpose

This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.

Official Title

PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS

Eligibility Criteria

Ages Eligible for Study: Older than 15 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * histologically or cytologically proven diagnosis of malignancy other than NSCLC* positive for translocation or inversion event involving the ALK gene locus* positive for ALK amplification events* positive for ALK activating point mutations
Exclusion Criteria:
  1. * mutations of amplifications involving the c-Met gene but not the ALK gene* concurrent treatment on another therapeutic clinical trial* prior therapy specifically directed against ALK
View All Criteria
Show Less

Investigator(s)

Michael P Link

Contact us to find out if this trial is right for you.

Contact

Alyson Falwell
650-736-4281

View on ClinicalTrials.gov